Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2017

View Archived Issues

Celgene agrees to acquire Delinia

Gene therapy GS-030 receives U.S. orphan status for retinitis pigmentosa

New trial will explore 5-ALA to prevent reduction in cardiac output after heart bypass surgery

Therapicon's melatonin formulation named U.S. orphan drug for necrotizing enterocolitis

Topline results from two pivotal phase III trials of SB-204 in patients with acne vulgaris

Ramot and Merck collaborate to develop antibody-drug conjugates for cancer

EMA's CHMP supports approval of Revlimid for post-ASCT maintenance therapy in MM

EMA committee gives positive opinion for Pfizer's Xeljanz

GreenPeptide initiates phase II trial of GRN-1201 for NSCLC in U.S.

Biogen presents promising data for the novel radiotracer MK-6240

Recordati's Cystadrops approved in E.U.

Scancell and Addario Lung Cancer Medical Institute collaborate on trials of SCIB-2

Phase Ib results for oral CC-122 in patients with advanced hepatocellular carcinoma

FDA approves Latuda to treat schizophrenia in adolescents

Amgen receives positive opinion for biosimilar adalimumab ABP-501

FDA maintains clinical hold on Regulus' RG-101 program

Topline results from phase III chronic constipation trial of linaclotide in Japan

GlaxoSmithKline discovers novel BMP-1 and TLL1/2 inhibitors

Sage Therapeutics presents new NMDA receptor ligands

Piramal Enterprises to acquire intrathecal spasticity and pain management drugs from Mallinckrodt

ViiV Healthcare UK identifies novel HIV integrase inhibitors

Research Council of Norway grant supports Bionor's development of Vacc-4x for HIV

Losartan given with FOLFIRINOX in phase II trial in locally advanced pancreatic cancer

Results from phase Ib trial of AM-0010 plus FOLFOX in metastatic pancreatic adenocarcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...